Tylenol sales in South Korean convenience stores drastically increased by as much as 99.6 percent from April to May on rumors that it helps with the fever, headache, and muscle pain that are common COVID-19 vaccine side effects.
With more South Koreans getting vaccinated for COVID-19, Tylenol is increasingly sold out at pharmacies, prompting consumers to head out to convenience stores to buy it.
Some consumers are hoarding Tylenol in anticipation of a supply crisis just like what happened with hand sanitizers and protective masks during the early stages of the pandemic.
.7-Eleven saw a 99.6 percent increase in Tylenol sales between May 27 and 30 soon after the introduction of the reservation service for ‘no-show’ vaccines, from the same period in April.
CU reported an 89.9 percent increase in Tylenol sales between May 27 and 31 from the same period in April. It was also a 125.5 percent increase compared to the same month last year,
GS25 posted a 38.8 percent increase in May from April, which was a 41.9 percent increase compared to the same month last year.
The Ministry of Food and Drug Safety reminded citizens that there are many other kinds of acetaminophen-based pain and fever reducers, offering information on some 70 similar drugs readily available in the country.


Treasury Buyback Fails to Cool Long-Term Yields
Hormuz Vessel Traffic Drops to Single Digits
Oil Prices Surge as Houthi Attacks Deepen Hormuz Supply Fears
Asian Stocks Steady as AI Shares Rebound Ahead of Fed Decision
Samsung, SK Hynix Reject KEPCO’s $18.7 Billion Power Funding Plan
Volkswagen Job Cuts Put Lower Saxony Leader Under Political Pressure
OpenAI Weighs AI Development Slowdown Over Safety Risks
Goldman Sachs Forecasts Fed Rate Hike as Inflation Risks Rise
Central Banks Could Buy 20,000 Tonnes of Gold: BofA
UK Businesses Urge Government to Cut Electricity Levies
OpenAI Rules Out 2026 IPO as Altman Prioritizes AI Safety
Nvidia Eyes $10 Billion Investment in Anthropic IPO
Ares Names James Garforth Principal for Asia Direct Lending
Hyundai Delays In-House ADAS, Turns to Nvidia
Asian Tech Stocks Slide as AI Concerns and Rising Bond Yields Hit Chipmakers
Novartis M&A Strategy Faces Investor Scrutiny After Drug Setbacks 



